Veracyte, Inc. has grown revenue 20% a year over three years and 29% a year over five. Revenue growth, 3-year annual rate: +20% (Diagnostics & Research median +8.4%). Revenue growth, 5-year rate: +29%, growth has slowed since the five-year average. Years of annual history on file: 15, FY2011 to FY2025, as filed.

VCYTVeracyte, Inc.

Healthcare

$45.23+33% 1Y

$45.23

$30.0152 weeks$59.55

Is it growing?

Excellent

Growing: revenue growing +17% year on year, earnings up +324% year on year, and operating margin widening (+15.8 points).

3 good

Revenue trend+17% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +29% a year.

Earnings trend+324% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing faster than revenue, so margins or the share count are helping.

Margin direction+15.8 points operating

Trailing-twelve-month operating margin, 18.9% now against 3.1% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Revenue growth, 3 yearsbetter than 88% of the market

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is VCYT growing?

Veracyte, Inc. has grown revenue 20% a year over three years and 29% a year over five.

+20%

Revenue growth, 3-year annual rate · Diagnostics & Research median +8.4% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +29%
Revenue growth, 5-year rate · +20% over three · growth has slowed since the five-year average
Years of annual history on file: 15
Years of annual history on file · FY2011 to FY2025, as filed

Details›